Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease

Neurobiology of Disease

Volumn 66, Issue , 2014, Pages 19-27

  Choi, M L ^a   Begeti, F ^a,b   Oh, J H ^c   Lee, S Y ^c   O'Keeffe, G C ^a   Clelland, C D ^a   Tyers, P ^a   Cho, Z H ^a   Kim, Y B ^a   Barker, R A ^a,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Gachon University College of Medicine   (South Korea)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Adult hippocampal neurogenesis; Dopamine; Huntington's disease

Indexed keywords

DOPAMINE 2 RECEPTOR; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DENTATE GYRUS; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOWN REGULATION; FOREBRAIN; HIPPOCAMPUS; HUNTINGTON CHOREA; MOTOR PERFORMANCE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER;

ADULT HIPPOCAMPAL NEUROGENESIS; DOPAMINE; HUNTINGTON'S DISEASE;

ANIMALS; BRAIN; CORPUS STRIATUM; DENTATE GYRUS; DOPAMINE; DOPAMINE ANTAGONISTS; FEMALE; HIPPOCAMPUS; HUNTINGTON DISEASE; MEDIAL FOREBRAIN BUNDLE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURAL STEM CELLS; NEUROGENESIS; OXIDOPAMINE; RECEPTORS, DOPAMINE D2; SULPIRIDE;

EID: 84896307597     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.02.004     Document Type: Article

References (72)

1. Andrews T.C., Weeks R.A., Turjanski N., Gunn R.N., Watkins L.H., Sahakian B., Hodges J.R., Rosser A.E., Wood N.W., Brooks D.J. Huntington's disease progression. PET and clinical observations. Brain 1999, 122(Pt 12):2353-2363.
2. Backhouse B., Barochovsky O., Malik C., Patel A.J., Lewis P.D. Effects of haloperidol on cell proliferation in the early postnatal brain. Neuropathol. Appl. Neurobiol. 1982, 8:109-116.
3. Bäckman L., Farde L. Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. Scand. J. Psychol. 2001, 42:287-296.
4. Benn C.L., Fox H., Bates G.P. Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. Mol. Neurodegener. 2008, 3:17.
5. Benn C.L., Luthi-Carter R., Kuhn A., Sadri-Vakili G., Blankson K.L., Dalai S.C., Goldstein D.R., Spires T.L., Pritchard J., Olson J.M., Van Dellen A., Hannan A.J., Cha J.H. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J. Neuropathol. Exp. Neurol. 2010, 69:817-827.
6. Blackwell A.D., Paterson N.S., Barker R.A., Robbins T.W., Sahakian B.J. The effects of modafinil on mood and cognition in Huntington's disease. Psychopharmacology (Berl) 2008, 199:29-36.
7. Borta A., Höglinger G.U. Dopamine and adult neurogenesis. J. Neurochem. 2007, 100:587-595.
8. Brooks S.P., Janghra N., Workman V.L., Bayram-Weston Z., Jones L., Dunnett S.B. Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice. Brain Res. Bull. 2012, 88:94-103.
9. Cha J.-H.J., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. 1998, 95:6480-6485.
10. Charvin D., Vanhoutte P., Pagès C., Borelli E., Caboche J. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12218-12223.
11. Clelland C.D., Choi M., Romberg C., Clemenson G.D., Fragniere A., Tyers P., Jessberger S., Saksida L.M., Barker R.A., Gage F.H., Bussey T.J. A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science 2009, 325:210-213.
12. Crook Z.R., Housman D.E. Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7487-7492.
13. Cummings D.M., Milnerwood A.J., Dallerac G.M., Waights V., Brown J.Y., Vatsavayai S.C., Hirst M.C., Murphy K.P. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:2856-2868.
14. Cyr M., Beaulieu J.-M., Laakso A., Sotnikova T.D., Yao W.-D., Bohn L.M., Gainetdinov R.R., Caron M.G. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc. Natl. Acad. Sci. 2003, 100:11035-11040.
15. Dallerac G.M., Vatsavayai S.C., Cummings D.M., Milnerwood A.J., Peddie C.J., Evans K.A., Walters S.W., Rezaie P., Hirst M.C., Murphy K.P. Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: rescue by D1 dopamine receptor activation. Neurodegener. Dis. 2011, 8:230-239.
16. Dawirs R.R., Hildebrandt K., Teuchert-Noodt G. Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus. J. Neural Transm. 1998, 105:317-327.
17. Duan W., Peng Q., Masuda N., Ford E., Tryggestad E., Ladenheim B., Zhao M., Cadet J.L., Wong J., Ross C.A. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis. 2008, 30:312-322.
18. Garrett M.C., Soares-Da-Silva P. Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission. J. Neurochem. 1992, 58:101-106.
19. Gasbarri A., Sulli A., Packard M.G. The dopaminergic mesencephalic projections to the hippocampal formation in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 1997, 21:1-22.
20. Gil J.M.A.C., Mohapel P., Araújo I.M., Popovic N., Li J.-Y., Brundin P., Petersén Å. Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. Neurobiol. Dis. 2005, 20:744-751.
21. Ginovart N., Lundin A., Farde L., Halldin C., Backman L., Swahn C.G., Pauli S., Sedvall G. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997, 120(Pt 3):503-514.
22. Glass M., Van Dellen A., Blakemore C., Hannan A.J., Faull R.L. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 2004, 123:207-212.
23. Grote H.E., Hannan A.J. Regulators of adult neurogenesis in the healthy and diseased brain. Clin. Exp. Pharmacol. Physiol. 2007, 34:533-545.
24. Grote H.E., Bull N.D., Howard M.L., Van Dellen A., Blakemore C., Bartlett P.F., Hannan A.J. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur. J. Neurosci. 2005, 22:2081-2088.
25. Hagihara H., Toyama K., Yamasaki N., Miyakawa T. Dissection of hippocampal dentate gyrus from adult mouse. J. Vis. Exp. 2009, 17:1543.
26. Hickey M.A., Reynolds G.P., Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 2002, 81:46-59.
27. Hoglinger G.U., Rizk P., Muriel M.P., Duyckaerts C., Oertel W.H., Caille I., Hirsch E.C. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci. 2004, 7:726-735.
28. Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66:366-372.
29. Jahanshahi A., Vlamings R., Kaya A.H., Lim L.W., Janssen M.L., Tan S., Visser-Vandewalle V., Steinbusch H.W., Temel Y. Hyperdopaminergic status in experimental Huntington disease. J. Neuropathol. Exp. Neurol. 2010, 69:910-917.
30. Jakel R.J., Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 2000, 23:239-245.
31. Jones B.J., Roberts D.J. The quantitative measurement of motor inco-ordination in naive mice using an accelerating rotarod. J. Pharm. Pharmacol. 1968, 20:302-304.
32. Kim J.S., Lee J.S., Im K.C., Kim S.J., Kim S., Lee D.S., Moon D.H. Performance measurement of the microPET Focus 120 scanner. J. Nucl. Med. 2007, 48:1527-1535.
33. Kim H.A., Jiang L., Madsen H., Parish C.L., Massalas J., Smardencas A., O'Leary C., Gantois I., O'Tuathaigh C., Waddington J.L., Ehrlich M.E., Lawrence A.J., Drago J. Resolving pathobiological mechanisms relating to Huntington disease: gait, balance, and involuntary movements in mice with targeted ablation of striatal D1 dopamine receptor cells. Neurobiol. Dis. 2014, 62:323-337.
34. Kippin T.E., Kapur S., Van Der Kooy D. Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J. Neurosci. 2005, 25:5815-5823.
35. Lalchandani R.R., Van Der Goes M.S., Partridge J.G., Vicini S. Dopamine D2 receptors regulate collateral inhibition between striatal medium spiny neurons. J. Neurosci. 2013, 33:14075-14086.
36. Lazic S.E., Grote H., Armstrong R.J.E., Blakemore C., Hannan A.J., Van Dellen A., Barker R.A. Decreased hippocampal cell proliferation in R6/1 Huntington's mice. NeuroReport 2004, 15:811-813.
37. Lazic S.E., Grote H.E., Blakemore C., Hannan A.J., Van Dellen A., Phillips W., Barker R.A. Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur. J. Neurosci. 2006, 23:1829-1838.
38. Leranth C., Hajszan T. Extrinsic afferent systems to the dentate gyrus. Prog. Brain Res. 2007, 163:63-84.
39. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996, 16:834-840.
40. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20:9104-9110.
41. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
42. Mason S.L., Barker R.A. Emerging drug therapies in Huntington's disease. Expert Opin. Emerg. Drugs 2009, 14:273-297.
43. McLaughlin B.A., Nelson D., Erecińska M., Chesselet M.F. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem. 1998, 70:2406-2415.
44. Ming G.-L., Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 2011, 70:687-702.
45. Mu Y., Zhao C., Gage F.H. Dopaminergic modulation of cortical inputs during maturation of adult-born dentate granule cells. J. Neurosci. 2011, 31:4113-4123.
46. O'Keeffe G.C., Tyers P., Aarsland D., Dalley J.W., Barker R.A., Caldwell M.A. Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc. Natl. Acad. Sci. 2009, 106:8754-8759.
47. Ortiz A.N., Kurth B.J., Osterhaus G.L., Johnson M.A. Impaired dopamine release and uptake in R6/1 Huntington's disease model mice. Neurosci. Lett. 2011, 492:11-14.
48. Pang T.Y., Du X., Zajac M.S., Howard M.L., Hannan A.J. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 2009, 18:753-766.
49. Paoletti P., Vila I., Rife M., Lizcano J.M., Alberch J., Gines S. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J. Neurosci. 2008, 28:10090-10101.
50. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., Robbins T.W., Sahakian B.J., Dunnett S.B., Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003, 126:1127-1135.
51. Pavese N., Politis M., Tai Y.F., Barker R.A., Tabrizi S.J., Mason S.L., Brooks D.J., Piccini P. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol. Dis. 2010, 37:356-361.
52. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego, (Book). second ed.
53. Petersén Å., Larsen K.E., Behr G.G., Romero N., Przedborski S., Brundin P., Sulzer D. Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum. Mol. Genet. 2001, 10:1243-1254.
54. Petersen A., Puschban Z., Lotharius J., Nicniocaill B., Wiekop P., O'Connor W.T., Brundin P. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol. Dis. 2002, 11:134-146.
55. Phillips W., Morton A.J., Barker R.A. Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. J. Neurosci. 2005, 25:11564-11576.
56. Priller J., Ecker D., Landwehrmeyer B., Craufurd D. A Europe-wide assessment of current medication choices in Huntington's disease. Mov. Disord. 2008, 23:1788.
57. Ramos E.M., Latourelle J.C., Gillis T., Mysore J.S., Squitieri F., Di Pardo A., Di Donato S., Gellera C., Hayden M.R., Morrison P.J., Nance M., Ross C.A., Margolis R.L., Gomez-Tortosa E., Ayuso C., Suchowersky O., Trent R.J., McCusker E., Novelletto A., Frontali M., Jones R., Ashizawa T., Frank S., Saint-Hilaire M.H., Hersch S.M., Rosas H.D., Lucente D., Harrison M.B., Zanko A., Abramson R.K., Marder K., Gusella J.F., Lee J.M., Alonso I., Sequeiros J., Myers R.H., Macdonald M.E. Candidate gluta matergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics 2013, 14:173-179.
58. Renoir T., Pang T.Y., Zajac M.S., Chan G., Du X., Leang L., Chevarin C., Lanfumey L., Hannan A.J. Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise. Br. J. Pharmacol. 2012, 165:1375-1389.
59. Reynolds D.S., Carter R.J., Morton A.J. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J. Neurosci. 1998, 18:10116-10127.
60. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
61. Rossato J.I., Bevilaqua L.R., Izquierdo I., Medina J.H., Cammarota M. Dopamine controls persistence of long-term memory storage. Science 2009, 325:1017-1020.
62. Sahay A., Scobie K.N., Hill A.S., O'Carroll C.M., Kheirbek M.A., Burghardt N.S., Fenton A.A., Dranovsky A., Hen R. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature 2011, 472:466-470.
63. Stack E.C., Dedeoglu A., Smith K.M., Cormier K., Kubilus J.K., Bogdanov M., Matson W.R., Yang L., Jenkins B.G., Luthi-Carter R., Kowall N.W., Hersch S.M., Beal M.F., Ferrante R.J. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J. Neurosci. 2007, 27:12908-12915.
64. Stephans S., Yamamoto B. Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity. Neuroscience 1996, 72:593-600.
65. Tang T.-S., Chen X., Liu J., Bezprozvanny I. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J. Neurosci. 2007, 27:7899-7910.
66. Turjanski N., Weeks R., Dolan R., Harding A.E., Brooks D.J. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995, 118(Pt 3):689-696.
67. Van Oostrom J.C., Dekker M., Willemsen A.T., De Jong B.M., Roos R.A., Leenders K.L. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease. Eur. J. Neurol. 2009, 16:226-231.
68. Von Bohlen und Halbach O. Immunohistological markers for proliferative events, gliogenesis, and neurogenesis within the adult hippocampus. Cell Tissue Res. 2011, 345:1-19.
69. Wakade C.G., Mahadik S.P., Waller J.L., Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 2002, 69:72-79.
70. Walker T.L., Turnbull G.W., MacKay E.W., Hannan A.J., Bartlett P.F. The latent stem cell population is retained in the hippocampus of transgenic Huntington's disease mice but not wild-type mice. PLoS ONE 2011, 6:e18153.
71. Wise R.A. Dopamine, learning and motivation. Nat. Rev. Neurosci. 2004, 5:483-494.
72. Yang P., Arnold S.A., Habas A., Hetman M., Hagg T. Ciliary neurotrophic factor mediates dopamine D2 receptor-induced CNS neurogenesis in adult mice. J. Neurosci. 2008, 28:2231-2241.